<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1110</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2019-7-8-24-26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>How to help patients with nephrogenic anemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Prozherina</surname><given-names>Yuliya</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">Remedium</aff><pub-date date-type="epub" iso-8601-date="2019-12-07" publication-format="electronic"><day>07</day><month>12</month><year>2019</year></pub-date><issue>7-8</issue><fpage>24</fpage><lpage>26</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2019,</copyright-statement><copyright-year>2019</copyright-year></permissions><abstract>Chronic renal failure (CRF) is one of the urgent problems not only for nephrology, but also for many other related specialties. According to modern concepts, anemia of renal origin is considered the earliest and most frequent complication of chronic renal failure [1]. In this regard, one of the key tasks of modern medicine is to ensure the availability of modern drugs for the management of anemia in such patients.</abstract><kwd-group xml:lang="en"><kwd>nephrogenic anemia</kwd><kwd>erythropoietin</kwd><kwd>darbepoetin alpha</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>нефрогенная анемия</kwd><kwd>эритропоэтин</kwd><kwd>дарбэпоэтин альфа</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Крысанов И.С. с соавт. Фармакоэкономический анализ применения дарбэпоэтина альфа для коррекции анемии у пациентов c хронической почечной недостаточностью, находящихся на гемодиализе или на перитонеальном диализе. Фармакоэкономика. 2016;3:4-11.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Инструкция по применению к препарату Дарбэстим.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Шило В.Ю. с соавт. Первый российский биоаналог дарбэпоэтина альфа: результаты двойного слепого рандомизированного клинического исследования эффективности и безопасности у пациентов с нефрогенной анемией на программном гемодиализе. Клиническая нефрология. 2018;4:42-54.</mixed-citation></ref></ref-list></back></article>
